ALLMedicine™ Acute Myelomonocytic Leukemia Center
Research & Reviews 23 results
https://doi.org/10.1007/s11899-021-00632-6
Current Hematologic Malignancy Reports; Shallis RM, Siddon AJ et. al.
Apr 24th, 2021 - In this review, we provide a comprehensive and contemporary understanding of malignant monocytosis and provide a framework by which the appropriate diagnosis with malignant monocytosis can be rendered. Increasing data support the use of molecular ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052012
Medicine Ji J, Li Y et. al.
Apr 14th, 2021 - Pure erythroid leukemia is a rare subcategory of acute myeloid leukemia characterized by predominant immature erythroid population. Its occurrence subsequent to acute myelomonocytic leukemia has not been reported before. We reported this rare case...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921214
Molecular Cancer Therapeutics; Anami Y, Deng M et. al.
Sep 4th, 2020 - Acute myeloid leukemia (AML) is the most common and aggressive blood cancer in adults. In particular, significant unmet medical needs exist for effective treatment strategies for acute myelomonocytic leukemia (M4) and acute monocytic leukemia (M5)...
https://doi.org/10.21873/anticanres.14488
Anticancer Research; Thadi A, Lewis L et. al.
Sep 4th, 2020 - Anticancer peptide PNC-27 binds to HDM-2 protein on cancer cell membranes inducing the formation of cytotoxic transmembrane pores. Herein, we investigated HDM-2 membrane expression and the effect of PNC-27 treatment on human non-stem cell acute my...
https://emedicine.medscape.com/article/1977919-print
Jul 21st, 2020 - In the 2016 update to the 2008 World Health Organization (WHO) classification system,[1, 2] the category "acute myeloid leukemia [AML] not otherwise specified" [NOS])" excludes AML subtypes associated with recurrent genetic abnormalities such as:...
News 1 results
https://www.mdedge.com/hematology-oncology/article/102154/aml/outcomes-worse-secondary-and-therapy-related-aml-compared-de
Jennifer Kelly Shepphird
Aug 24th, 2015 - Clinical outcomes were significantly worse among younger patients with secondary and therapy-related acute myeloid leukemia (sAML and tAML, respectively) compared with de novo disease, suggesting the presence of distinct AML subtypes, in a study p.
